Baron & Budd Attorney and Shareholder Burton LeBlanc to Speak on Opioid Epidemic at American Association for Justice
BATON ROUGE, La. – November 17, 2017 – The national law firm of Baron & Budd is pleased to...READ MORE
Invokana is a drug used by diabetics to help remove excess sugar from the body through urination. However, there are some serious concerns being raised regarding the drug’s risks. Baron & Budd’s pharmaceutical attorneys may be able to help if you have been harmed after taking Invokana or a similar drug. Call 866-912-8281 or complete our contact form to learn more about your potential legal options.
The Institute for Safe Medication Practices (ISMP) issued a report in May that looked at the efficacy and safety of Invokana, which is manufactured by Johnson & Johnson subsidiary Janssen Pharmaceuticals. Invokana is one of a several drugs labeled as SGLT2 inhibitors, which block a protein (SGLT2) from performing its function of storing sugar in the body. Other drugs in this class include:
The ISMP report raised concerns over not only the side effects of Invokana – which include diabetic ketoacidosis and potential kidney failure – but also the clinical trials that helped the medication gain U.S. Food and Drug Administration approval.
According to ISMP, federal drug regulators received more than 450 reports of adverse events associated with Invokana use within the first year after the drug was approved. Problems included the following:
Patients and healthcare professionals alike are questioning why Invokana received FDA approval, since it posed such a high risk of complications.
The ISMP noted that Janssen representatives pointed out that these and other risks were posted on the drug’s warning label, with the exception of kidney stones. However, the ISMP stated that Invokana had not been sufficiently tested to ensure that its benefits justified those risks. ISMP researchers found that Invokana was associated with more serious adverse reports than more than 90 percent of other medications monitored on a regular basis.
According to the ISMP, even though the drug was tested in more than 10,000 people, there was not enough data accumulated during the clinical trials to determine whether Invokana provided a “measurable clinical benefit.” There was also not enough data, the ISMP reported, to fully determine whether or not long-term use of Invokana could lead to cardiovascular problems, increased bone fracture risk, or decline in kidney function.